- Home
- NCRA vs BGMS Comparison
NCRA vs BGMS Comparison
Compare NCRA & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCRA | BGMS |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | Taiwan | Malaysia |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.0M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCRA | BGMS |
|---|---|---|
| Price | $0.20 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 416.0K | 69.0K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.73 |
| 52 Week High | $2.40 | $6.70 |
Technical Indicators
Market Signals| Indicator | NCRA | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 30.84 | 49.98 |
| Support Level | $0.18 | $0.74 |
| Resistance Level | $0.32 | $1.13 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 15.48 | 49.84 |
Price Performance
Historical ComparisonAbout NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.